首页> Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer> ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen.

ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen.

导出原文传递

翻译打印收藏纠错

第一作者： Merdol,Ibrahim

第一单位： U.K. National External Quality Assessment Scheme Immunocytochemistry and In Situ Hybridisation, University College London Cancer Institute, Research Department of Pathology, University College London, United Kingdom. Electronic address: merdol.ibrahim@ucl.ac.uk.

作者： Merdol,Ibrahim ^[1] ; Suzanne,Parry ^[2] ; Dawn,Wilkinson ^[2] ; Neil,Bilbe ^[2] ; David,Allen ^[3] ; Steven,Forrest ^[4] ; Perry,Maxwell ^[5] ; Anthony,O'Grady ^[6] ; Jane,Starczynski ^[7] ; Philippe,Tanier ^[8] ; John,Gosney ^[4] ; Keith,Kerr ^[9] ; Keith,Miller ^[2] ; Erik,Thunnissen ^[10]

作者单位： U.K. National External Quality Assessment Scheme Immunocytochemistry and In Situ Hybridisation, University College London Cancer Institute, Research Department of Pathology, University College London, United Kingdom. Electronic address: merdol.ibrahim@ucl.ac.uk. ^[1] U.K. National External Quality Assessment Scheme Immunocytochemistry and In Situ Hybridisation, University College London Cancer Institute, Research Department of Pathology, University College London, United Kingdom. ^[2] University College London Advanced Diagnostics, Research Department of Pathology, University College London, United Kingdom. ^[3] Royal Liverpool University Hospital, Liverpool, United Kingdom. ^[4] Northern Ireland Molecular Pathology Laboratory, Belfast Health and Social Care Trust and Queen's University Belfast, Northern Ireland, United Kingdom. ^[5] Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland. ^[6] Birmingham Heartlands Hospital, Birmingham, United Kingdom. ^[7] Queen Elizabeth Hospital, Birmingham, United Kingdom. ^[8] Aberdeen Royal Infirmary, Aberdeen, United Kingdom. ^[9] Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. ^[10]

关键词 ALK IHC External quality assessment Immunohistochemistry NSCLC

医学主题词人类(Humans);免疫组织化学(Immunohistochemistry);受体蛋白质酪氨酸激酶类(Receptor Protein-Tyrosine Kinases)

DOI 10.1016/j.jtho.2016.07.012

PMID 27468935

发布时间 2021-10-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交